Too often, recruiters are more clear on what a position will “do” rather than what it will “achieve”.Outlining tasks and responsibilities takes priority over goals and impact.But to attract top talent, you need to define and explain what success looks…
HOME > BUSINESS
BUSINESS
- Opdivo Extends OS in Advanced Gastric Cancer: Ono
January 23, 2017
- Takeda Taps NY Biotech to Develop Its Pediatric Epilepsy Med
January 20, 2017
- Daiichi Sankyo’s 2nd ADC Now in Japan PI/II for HER3-Positive Breast Cancer
January 20, 2017
- Hiroshi Kasamoto Named as Bioverativ Japan President
January 20, 2017
- JCR to Initiate PI/II Study in March of Therapeutic Enzyme for Hunter Syndrome that Applies Blood-Brain Barrier Technology
January 20, 2017
- Ethical Drug Sales Down 3.6% in November: Crecon Report
January 19, 2017
- Gilead Japan to Switch Sovaldi, Harvoni Bottles to Blister Packs
January 19, 2017
- Nichi-Iko, Meiji Seika Pharma Obtain New Indications for Zosyn Generics
January 19, 2017
- Gilead Asks Pharmacists to Open Harvoni Bottles in Front of Patients after Fake Drug Found
January 18, 2017
- Mitsubishi Tanabe to Shake Up Organization in April
January 17, 2017
- Eisai to Take Over Rights to Roche/Chugai’s Insomnia Drug
January 17, 2017
- FDA Orphan Status Granted to Nippon Shinyaku’s DMD Med
January 17, 2017
- Dasotraline Meets Primary Endpoint in PII/III Study in Adult Patients with Binge Eating Disorder: Sumitomo Dainippon
January 17, 2017
- Hisamitsu Suffers Double-Digit Plunge in March-November Sales
January 16, 2017
- Shionogi’s Novel Antibacterial Shows Effectiveness in Urinary Tract Infection
January 13, 2017
- SBI Biotech Licenses Autoimmune Disease Med to Kyowa Kirin
January 13, 2017
- Takeda Invests US$125 Million in Maverick for T-Cell Therapy, Buyout Eyed
January 13, 2017
- AbbVie’s 8-Week Hep C Med Delivers High SVR12 Rate in Japanese
January 13, 2017
- Imigran AG to Get Off Strong Start: Aspen Japan
January 12, 2017
- Astellas Bows Out from Flu Vaccine Development Pact with UMN
January 11, 2017
ページ
Pharmaceutical companies are giving high marks to Japan’s drug pricing reform for FY2024. According to a survey conducted by Jiho, 51% of all respondents expressed a positive opinion of the reform, saying that they were “somewhat satisfied” with it. The…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…